Product Dossier
APO-ARIPIPRAZOLE
Product Dossier for APO-ARIPIPRAZOLE (aripiprazole, Arrotex Pharmaceuticals). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: Arrotex Pharmaceuticals
- Active ingredient: aripiprazole
- Therapeutic area: Psychiatry
- Related brand: ABILIFY
- Related brand: ABILIFY
- Related brand: ARIZOLE
- Same area: REXULTI
- Same area: NICORETTE
What it is
APO-ARIPIPRAZOLE is an aripiprazole tablet product sponsored by Arrotex Pharmaceuticals. APO-ARIPIPRAZOLE is available in strengths of 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg.
Approved indications
The available source documents do not contain information about the approved indications for APO-ARIPIPRAZOLE tablets. The clinical information provided relates to Abilify Maintena, a different formulation.
Dosing overview
The available source documents do not contain dosing information for APO-ARIPIPRAZOLE tablets.
Key safety warnings
The available source documents do not contain safety warning information for APO-ARIPIPRAZOLE tablets.
Contraindications
The available source documents do not contain contraindication information for APO-ARIPIPRAZOLE tablets.
PBS listing
The available source documents do not contain PBS listing information for APO-ARIPIPRAZOLE.
Regulatory history
APO-ARIPIPRAZOLE tablets in strengths of 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg were first listed on the ARTG on 9 July 2009.